Potential use of aptamers for diagnosis and treatment of pancreatic cancer

Ge Gao,Can Liu,Sona Jain,Dai Li,Hai Wang,Yongxin Zhao,Juewen Liu
DOI: https://doi.org/10.1080/1061186X.2018.1564924
2019-10-04
Journal of Drug Targeting
Abstract:Pancreatic cancer (PC) is highly malignant with a low 5-year survival rate. PC currently does not have good early diagnostic markers and responses poorly to chemotherapeutic drugs. The search for better biomarkers and developing more effective chemotherapy are important ways to improve the healthcare of PC patients. Aptamers are single-stranded nucleic acids with high binding affinity and specificity to target molecules. Many aptamers against different forms of cancer including PC have been selected for both diagnostic and therapeutic use. Aptamers can work as ligands to distinguish tumour cells from normal cells. Using cells as selection targets, the obtained aptamers have been used to discover new cancer biomarkers after identification of the binding target. Aptamers have been shown to have antagonists effect on cancer cell proliferation, apoptosis, and metastasis. In addition, aptamers have been used as carriers to deliver therapeutic agents to selectively kill PC cells. This review summarises the potential use of aptamers in the diagnosis and treatment of PC.
pharmacology & pharmacy
What problem does this paper attempt to address?